Fzata, Inc.
Fzata is dedicated to expanding safety, efficacy, and access for therapeutic biologics through innovative oral biologics leveraging BioPYM platform. Their mission is to develop first-in-class live yeast medicines for GI diseases and gut-brain axis disorders, aiming to revolutionize biologic delivery with no needles, no infusions, and no refrigeration, while ensuring safety and cost-effectiveness.
Industries
Nr. of Employees
small (1-50)
Fzata, Inc.
Patents
Humanized tetra-specific octavalent antibody against clostridium difficile toxin A and B
US-12077575-B2
View Details
Humanized tetra-specific octavalent antibody against clostridium difficile toxin A and B
US-12077575-B2
View DetailsProducts
FZ002 (live biotherapeutic yeast candidate for Clostridioides difficile)
A first-in-class live yeast biotherapeutic candidate engineered to produce therapeutic proteins in the gut to treat C. difficile infection; advanced through preclinical studies, cGMP manufacturing, and clinical trial agreements toward IND/Phase 1 readiness.
FZ006 (oral biologic candidate for visceral pain/IBD-related indications)
An investigational oral live biotherapeutic program described as targeting visceral pain and inflammatory bowel disease–related indications, supported by grant funding and development planning.
FZ002 (live biotherapeutic yeast candidate for Clostridioides difficile)
A first-in-class live yeast biotherapeutic candidate engineered to produce therapeutic proteins in the gut to treat C. difficile infection; advanced through preclinical studies, cGMP manufacturing, and clinical trial agreements toward IND/Phase 1 readiness.
FZ006 (oral biologic candidate for visceral pain/IBD-related indications)
An investigational oral live biotherapeutic program described as targeting visceral pain and inflammatory bowel disease–related indications, supported by grant funding and development planning.
Services
Partnerships with biotech and pharmaceutical firms for joint research, co-development, and access to platform capabilities to accelerate biologic candidate development.
Engagements to support clinical trial initiation through trial agreements and IND-enabling work for platform candidates.
Partnerships with biotech and pharmaceutical firms for joint research, co-development, and access to platform capabilities to accelerate biologic candidate development.
Engagements to support clinical trial initiation through trial agreements and IND-enabling work for platform candidates.
Expertise Areas
- Oral live biotherapeutics
- Biologic antibody engineering and multi-specific formats
- Gastrointestinal therapeutics and gut-targeted delivery
- Infectious disease therapeutics (Clostridioides difficile)
Key Technologies
- Recombinant probiotic yeast expression systems
- Plug-and-play genomic insertion constructs
- Lyophilization for live biologics
- Oral capsule delivery systems for GI targeting
News & Updates
Recognition and awards received by Fzata, including finalist at BIO 2024 International Start-up Stadium, $7MM grant for FZ006 program, and winner of the Global Health Innovation Challenge II.
Fzata announced its plan to pitch the BioPYM platform at the 2023 Biotech Showcase.
Fzata was honored as the Biotechnology winner at the 12th annual Mid-Atlantic Innovation Celebration Award program, showcasing the region’s greatest and most creative minds at work.
Fzata's lead drug FZ002 has advanced to manufacturing and IND-enabling studies, representing a groundbreaking platform for oral delivery of live biologics.
Fzata received multiple NIH grants supporting development of serological assays and immunotherapies for C. diff and IBD.
Research on FZ002 was published in Science Translational Medicine, highlighting its potential as a novel therapeutic.
Recognition and awards received by Fzata, including finalist at BIO 2024 International Start-up Stadium, $7MM grant for FZ006 program, and winner of the Global Health Innovation Challenge II.
Fzata announced its plan to pitch the BioPYM platform at the 2023 Biotech Showcase.
Fzata was honored as the Biotechnology winner at the 12th annual Mid-Atlantic Innovation Celebration Award program, showcasing the region’s greatest and most creative minds at work.
Fzata's lead drug FZ002 has advanced to manufacturing and IND-enabling studies, representing a groundbreaking platform for oral delivery of live biologics.
Fzata received multiple NIH grants supporting development of serological assays and immunotherapies for C. diff and IBD.
Research on FZ002 was published in Science Translational Medicine, highlighting its potential as a novel therapeutic.